Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin in Advanced CKD
NCT05309785Phase 4Completed
- Sponsor
- McGill University Health Centre
- Start
- Nov 2022
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of canagliflozin in chronic kidney disease (CKD) and end stage renal disease (ESRD) (2 arms), sponsored by McGill University Health Centre. Primary endpoints: Urine Albumin to Creatinine Ratio at 26 weeks and Area Under the Curve from 0 to 24 hours. Started Nov 2022; status: completed.
02
Drugs
canagliflozin
03
Conditions
chronic kidney disease (CKD)end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT05309785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05309785.